PRDM9 and cervical carcinoma: In fact, Aurora kinase inhibitors have been shown to suppress proliferation of cervical cancer cells and enhance chemosensitivity[40,41], suggesting that targeting Aurora in combination with the HP1-histone methyltransferase pathway may be a beneficial therapy in these patients.